LGND Ligand Pharmaceuticals Incorporated Stock Quote

LGND [NASD]

Index	-	P/E	-	EPS (ttm)	-0.20	Insider Own	4.40%	Shs Outstand	16.07M	Perf Week	-2.58%
Market Cap	2.43B	Forward P/E	29.69	EPS next Y	4.86	Insider Trans	-23.38%	Shs Float	15.28M	Perf Month	-18.65%
Income	-3.00M	PEG	-	EPS next Q	1.12	Inst Own	-	Short Float	17.95%	Perf Quarter	73.06%
Sales	186.40M	P/S	13.05	EPS this Y	-100.60%	Inst Trans	-0.38%	Short Ratio	4.23	Perf Half Y	39.90%
Book/sh	44.14	P/B	3.27	EPS next Y	-21.17%	ROA	-0.20%	Target Price	224.67	Perf Year	35.42%
Cash/sh	24.42	P/C	5.91	EPS next 5Y	24.20%	ROE	-0.40%	52W Range	57.24 - 219.75	Perf YTD	45.20%
Dividend	-	P/FCF	44.54	EPS past 5Y	-15.10%	ROI	2.90%	52W High	-34.29%	Beta	1.23
Dividend %	-	Quick Ratio	4.70	Sales past 5Y	21.00%	Gross Margin	83.70%	52W Low	152.27%	ATR	15.04
Employees	155	Current Ratio	5.00	Sales Q/Q	159.30%	Oper. Margin	13.90%	RSI (14)	44.58	Volatility	7.31% 8.82%
Optionable	Yes	Debt/Eq	0.63	EPS Q/Q	183.80%	Profit Margin	-1.60%	Rel Volume	0.55	Prev Close	141.71
Shortable	Yes	LT Debt/Eq	0.62	Earnings	Feb 03 BMO	Payout	-	Avg Volume	649.26K	Price	144.40
Recom	2.20	SMA20	-12.30%	SMA50	1.18%	SMA200	28.32%	Volume	360,227	Change	1.90%

Feb-04-21

Reiterated

H.C. Wainwright

Buy

$229 → $310

Oct-06-20

Initiated

Barclays

Overweight

$156

Mar-24-20

Downgrade

Argus

Buy → Hold

Mar-10-20

Initiated

Guggenheim

Neutral

Feb-06-20

Initiated

The Benchmark Company

Buy

$135

Sep-19-19

Upgrade

Barclays

Equal Weight → Overweight

$110 → $132

Jun-11-19

Initiated

Barclays

Equal Weight

$131

May-03-19

Reiterated

H.C. Wainwright

Buy

$254 → $214

Mar-06-19

Reiterated

H.C. Wainwright

Buy

$281 → $254

Oct-29-18

Upgrade

ROTH Capital

Neutral → Buy

Oct-02-18

Reiterated

H.C. Wainwright

Buy

$270 → $280

Sep-11-18

Reiterated

Argus

Buy

$260 → $300

Aug-17-18

Initiated

Goldman

Neutral

$256

Aug-08-18

Downgrade

ROTH Capital

Buy → Neutral

Jun-21-18

Initiated

Argus

Buy

$260

Dec-27-17

Reiterated

H.C. Wainwright

Buy

$163 → $169

Sep-05-17

Resumed

H.C. Wainwright

Buy

$150

Oct-05-16

Reiterated

H.C. Wainwright

Buy

$146 → $160

Aug-05-16

Downgrade

Deutsche Bank

Hold → Sell

$104 → $110

Mar-11-16

Initiated

Sidoti

Buy

Mar-05-21 11:30AM	Why Is Ligand (LGND) Down 21.3% Since Last Earnings Report? Zacks
Feb-25-21 09:55AM	Here Are The Stocks With The Highest Short Interest Rate Benzinga
Feb-17-21 12:44PM	Co-Diagnostics Clears Technical Benchmark, Hitting 90-Plus RS Rating Investor's Business Daily -7.59%
Feb-11-21 01:40PM	Stocks Reverse Lower, Seek To Rebound; Cannabis Stocks Routed Investor's Business Daily -14.62%
Feb-10-21 01:40PM	Heat Biologics Stock Notches Scorching RS Rating Investor's Business Daily
Feb-09-21 06:40AM	Forget Gamestop! This Highly Shorted Stock Is a Strong Buy Now Motley Fool
Feb-06-21 02:38AM	Earnings Update: Here's Why Analysts Just Lifted Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Price Target To US$225 Simply Wall St.
Feb-05-21 04:39PM	Dow Jones Rises For Fifth Straight Session As Nasdaq, Small Caps Lead Market Investor's Business Daily +12.72%
Feb-04-21 01:54PM	Anavex Life Sciences Crp Earns 94 RS Rating; Soars To Record High Investor's Business Daily
08:56AM	Ligand (LGND) Q4 Earnings & Sales Top, 2021 Guidance Raised Zacks
03:15AM	Is Ligand Pharmaceuticals' (NASDAQ:LGND) Share Price Gain Of 101% Well Earned? Simply Wall St.
Feb-03-21 01:30PM	Ligand Pharmaceuticals Inc (LGND) Q4 2020 Earnings Call Transcript Motley Fool
07:58AM	Ligand Pharmaceuticals: Q4 Earnings Insights Benzinga
07:30AM	Ligand Reports Fourth Quarter and Full Year 2020 Financial Results Business Wire
06:30AM	Ligand Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-02-21 11:59AM	Ligand Partner Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis Business Wire
Feb-01-21 02:57PM	Horizon Pharma Sees Rising Composite Rating To 96 Investor's Business Daily
Jan-28-21 08:04PM	Levi & Korsinsky LLP, National Class Action Law Firm, Announces Class Action Investigation Against Robinhood and Other Brokers on Behalf of Investors in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) Newsfile +17.58%
06:34PM	Whos the next GameStop? These are the 10 most shorted stocks Quartz
Jan-27-21 01:06PM	Stocks Showing Market Leadership: Sorrento Therapeutics Earns 93 RS Rating Investor's Business Daily
05:34AM	GameStop mania continues into Wednesday, with stock up 116% in premarket action MarketWatch
Jan-20-21 12:45PM	Top-Rated Stocks: Ligand Pharmaceuticals Sees Composite Rating Climb To 97 Investor's Business Daily
08:30AM	Ligands Fourth Quarter Financial Results to be Reported February 3rd Business Wire
Jan-19-21 04:18PM	Stocks Close Higher, Near Day's Highs; Solar Stocks Extend Rally Investor's Business Daily +5.97%
Jan-13-21 08:30AM	Ligand Receives Milestone Payment from Merck Business Wire
Dec-23-20 10:15AM	Biotech Stock Roundup: PFE/BNTX Vaccine Authorized in Europe, Updates From AMGN, & More Zacks
Dec-21-20 08:30AM	Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagens Discovery Technology to Target Neurological Disorders Business Wire
Dec-18-20 02:43PM	Is LGND A Good Stock To Buy According To Hedge Funds? Insider Monkey
Dec-17-20 09:19AM	20 best mid-cap stocks for 2021, according to analysts MarketWatch +5.13%
Dec-06-20 03:59AM	Does Ligand Pharmaceuticals (NASDAQ:LGND) Have A Healthy Balance Sheet? Simply Wall St.
Nov-29-20 11:30AM	Ligand (LGND) Up 3.4% Since Last Earnings Report: Can It Continue? Zacks
Nov-23-20 08:30AM	Ligand Announces Clinical and Regulatory Progress by Multiple Partners with OmniAb® Antibodies Business Wire
Nov-06-20 02:16PM	Ligands Partner Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT for the Treatment of Status Epilepticus in Adult and Pediatric Patients Business Wire
Nov-02-20 11:06AM	Ligand (LGND) Q3 Earnings & Sales Fall Short of Estimates Zacks
Oct-30-20 11:31PM	Ligand Pharmaceuticals Inc (LGND) Q3 2020 Earnings Call Transcript Motley Fool
09:25AM	Ligand Pharmaceuticals (LGND) Q3 Earnings and Revenues Miss Estimates Zacks
08:24AM	Recap: Ligand Pharmaceuticals Q3 Earnings Benzinga
08:00AM	Ligand Reports Third Quarter 2020 Financial Results Business Wire
06:45AM	Ligand Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Oct-28-20 12:00PM	What's in Store for Ligand (LGND) This Earnings Season? Zacks
Oct-26-20 11:55PM	4 Health Stocks Stonepine Capital Loves (1 Has Gained 233% Since September 29) Insider Monkey
Oct-23-20 12:30PM	Ligand Pharmaceuticals (LGND) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Zacks
08:30AM	Ligands Captisol Technology Plays Key Role in the Manufacture of Gileads Veklury, the First FDA-Approved COVID-19 Treatment Business Wire
Oct-22-20 04:42PM	FDA Approves Gilead's Remdesivir For Treatment Of Hospitalized COVID-19 Patients Benzinga +5.20%
10:50AM	A Look At The Fair Value Of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Simply Wall St.
Oct-20-20 02:05PM	Ligand Provides Highlights from Todays Investor Day Event Business Wire
Oct-19-20 04:02PM	Ligands Third Quarter Financial Results to be Reported October 30th Business Wire
Oct-06-20 09:25PM	Should I Avoid Ligand Pharmaceuticals Inc. (LGND)? Insider Monkey
Oct-05-20 05:47PM	Ligand: The Small Cap Powering Gilead's Remdesivir Benzinga
Oct-02-20 08:00AM	Ligand to Host Virtual Investor Day on October 20th Business Wire
02:30AM	Ligand Closes $438M Pfenex Deal; Street Sees 84% Upside SmarterAnalyst
Oct-01-20 08:24AM	Ligand Completes Acquisition of Pfenex Inc. Business Wire
Sep-30-20 08:00AM	Ligand Announces Expiration of Tender Offer for Shares of Pfenex Inc. Business Wire
Sep-25-20 11:40AM	LGND or ALKS: Which Is the Better Value Stock Right Now? Zacks
Sep-23-20 08:00AM	Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million Business Wire
Sep-18-20 07:16AM	Ligand Pharmaceuticals Enters Oversold Territory Zacks
Sep-10-20 08:00AM	Ligand Expands OmniAb® Antibody Discovery Platform Through the Acquisitions of xCella Biosciences and Taurus Biosciences Business Wire
Sep-09-20 11:40AM	LGND or ALKS: Which Is the Better Value Stock Right Now? Zacks
Sep-02-20 11:30AM	Ligand (LGND) Down 13.7% Since Last Earnings Report: Can It Rebound? Zacks
Sep-01-20 04:02PM	Ligand Pharmaceuticals Management to Present at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference Business Wire
Aug-31-20 09:00AM	Ligand Commences Previously Announced Cash Tender Offer to Acquire Pfenex Inc. Business Wire
Aug-25-20 04:15PM	Ligand OmniAb® Partner Immunovant Announced Positive Topline Results from Multicenter, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis Business Wire
Aug-24-20 11:40AM	LGND vs. ILMN: Which Stock Is the Better Value Option? Zacks
08:30AM	Ligand Announces Amgens KYPROLIS® Approved by FDA as Combination Regimen with DARZALEX® and Dexamethasone in Once- and Twice-Weekly Dosing Regimens for Patients with Relapsed/Refractory Multiple Myeloma Business Wire
Aug-20-20 10:46AM	What Did Ligand Pharmaceuticals' (NASDAQ:LGND) CEO Take Home Last Year? Simply Wall St.
Aug-12-20 10:32AM	(PFNX) Alert: Johnson Fistel Investigates Proposed Sale of Pfenex; Are Shareholders Getting a Fair Deal? PR Newswire
Aug-11-20 01:10PM	P/E Ratio Insights for Ligand Pharmaceuticals Benzinga -5.70%
08:20AM	The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September Benzinga
06:22AM	Pfenex Pops 59% On Ligand $513M Buy-Out Deal; Analyst Sees 93% Upside SmarterAnalyst
Aug-10-20 05:36PM	Ligand to Acquire Pfenex Inc. Business Wire
Aug-07-20 11:40AM	LGND vs. ILMN: Which Stock Should Value Investors Buy Now? Zacks
08:30AM	CStone Announces That OmniAb-derived CS1001 (Anti-PD-L1) Phase 3 Trial Met the Primary Endpoint as First-Line Treatment in Stage IV Squamous and Non-squamous Non-Small Cell Lung Cancer and Announces Plans to Submit a New Drug Application Business Wire
Aug-04-20 11:01AM	Ligand (LGND) Beats on Q2 Earnings & Sales, Raises View Zacks
Aug-03-20 02:10PM	Ligand Trounces Q2 Estimates by Helping Companies Make COVID-19 Drug Remdesivir Motley Fool
02:00PM	Ligand Pharmaceuticals Inc (LGND) Q2 2020 Earnings Call Transcript Motley Fool
08:55AM	Ligand Pharmaceuticals (LGND) Q2 Earnings and Revenues Beat Estimates Zacks
07:30AM	Ligand Reports Second Quarter 2020 Financial Results Business Wire
Aug-02-20 11:08AM	The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings Benzinga
Jul-16-20 04:28PM	Ligands Second Quarter Financial Results to be Reported August 3rd Business Wire
Jul-13-20 07:51AM	Functional, Human Antibodies Targeting SARS-CoV-2 Discovered Using IPA's Proprietary B cell Select and Single Step Cloning Hybridoma Technologies CNW Group
Jul-12-20 04:16PM	Were Hedge Funds Right About Ligand Pharmaceuticals Inc. (LGND)? Insider Monkey
Jul-08-20 10:00AM	Sermonix Pharmaceuticals to Collaborate With Eli Lilly and Company in Studying Combination of Lasofoxifene and Lillys CDK 4 and 6 Inhibitor, Abemaciclib, in Metastatic Breast Cancer GlobeNewswire
Jul-03-20 11:40AM	LGND or RGEN: Which Is the Better Value Stock Right Now? Zacks
Jun-29-20 12:48PM	IPA Confirms Discovery of Fully Human, Potent, Neutralizing Antibodies Targeting SARS-CoV-2 CNW Group
11:44AM	Ascendis Submits BLA to FDA for TransConhGH in Pediatric GHD Zacks
09:12AM	Vertex's Triple Combo Cystic Fibrosis Pill Gets CHMP Backing Zacks
Jun-17-20 11:40AM	LGND or RGEN: Which Is the Better Value Stock Right Now? Zacks
Jun-15-20 08:30AM	Ligand Announces an Expansion of Vernalis Collaboration with Servier for Research on Novel Oncology Targets Business Wire
Jun-08-20 02:04PM	Hedge Funds Piling Into Ligand Pharmaceuticals Inc. (LGND) Again Insider Monkey
Jun-05-20 11:31AM	Why Is Ligand (LGND) Up 16.3% Since Last Earnings Report? Zacks
Jun-04-20 10:45PM	Edited Transcript of LGND earnings conference call or presentation 6-May-20 8:30pm GMT Thomson Reuters StreetEvents
Jun-03-20 06:43PM	Ligand Pharmaceuticals Shows Improved Relative Price Performance; Still Shy Of Benchmark Investor's Business Daily +6.56%
Jun-01-20 04:53PM	Ligand CEO Issues Letter to Captisol Customers Business Wire
11:40AM	LGND or TECH: Which Is the Better Value Stock Right Now? Zacks
May-29-20 08:00AM	Ligand Announces Icagens Expansion of Collaboration with Roche to Develop and Commercialize Therapies for Neurological Diseases Business Wire
May-28-20 04:22PM	Ligand Earns $3 Million Milestone Payment from Palvella Therapeutics Business Wire
04:08PM	Palvella Therapeutics Completes $45 Million Series C Financing GlobeNewswire
May-22-20 08:58AM	Update: Ligand Pharmaceuticals (NASDAQ:LGND) Stock Gained 20% In The Last Five Years Simply Wall St.
May-14-20 11:50AM	Should Value Investors Buy Ligand Pharmaceuticals (LGND) Stock? Zacks
May-07-20 04:00PM	Ligand Pharmaceuticals Inc (LGND) Q1 2020 Earnings Call Transcript Motley Fool

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; and Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations. It also offers bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Minnebro for the treatment of hypertension; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KOZARICH JOHN W	Director	Feb 22	Option Exercise	10.12	2,500	25,300	29,708	Feb 23 05:18 PM
Davis Todd C	Director	Feb 11	Option Exercise	195.91	2,474	484,681	50,152	Feb 12 06:23 PM
Davis Todd C	Director	Feb 10	Sale	213.14	5,083	1,083,410	47,678	Feb 12 06:23 PM
Sabba Stephen L	Director	Feb 09	Option Exercise	11.32	14,670	166,138	39,101	Feb 11 04:06 PM
Sabba Stephen L	Director	Feb 09	Sale	208.53	14,670	3,059,123	24,431	Feb 11 04:06 PM
HIGGINS JOHN L	Chief Executive Officer	Feb 05	Option Exercise	12.16	114,666	1,394,017	346,030	Feb 09 06:08 PM
HIGGINS JOHN L	Chief Executive Officer	Feb 05	Sale	203.40	54,666	11,119,239	286,030	Feb 09 06:08 PM
FOEHR MATTHEW W	President and COO	Feb 04	Option Exercise	23.07	45,547	1,050,890	212,745	Feb 05 05:03 PM
FOEHR MATTHEW W	President and COO	Feb 04	Sale	176.86	44,547	7,878,582	168,198	Feb 05 05:03 PM
Berkman Charles S	SVP, Gen. Counsel & Secretary	Feb 04	Sale	178.50	18,097	3,230,376	28,906	Feb 05 05:03 PM
HIGGINS JOHN L	Chief Executive Officer	Jan 27	Option Exercise	17.66	70,000	1,236,400	283,422	Jan 27 07:04 PM
Davis Todd C	Director	Jan 27	Option Exercise	113.50	2,456	278,756	52,761	Jan 27 07:02 PM
HIGGINS JOHN L	Chief Executive Officer	Jan 27	Sale	182.00	40,000	7,280,000	243,422	Jan 27 07:04 PM
HIGGINS JOHN L	Chief Executive Officer	Jan 25	Option Exercise	14.47	50,000	723,500	285,310	Jan 27 07:04 PM
HIGGINS JOHN L	Chief Executive Officer	Jan 25	Sale	159.00	50,000	7,950,000	235,310	Jan 27 07:04 PM
HIGGINS JOHN L	Chief Executive Officer	Dec 08	Option Exercise	10.05	14,657	147,303	236,770	Dec 09 06:12 PM
HIGGINS JOHN L	Chief Executive Officer	Nov 09	Option Exercise	10.05	20,000	201,000	224,571	Nov 10 07:41 PM
Patel Sunil	Director	Nov 02	Buy	82.52	1,000	82,520	28,190	Nov 04 04:19 PM
FOEHR MATTHEW W	President and COO	Aug 24	Option Exercise	21.92	78	1,710	155,491	Aug 25 07:10 PM
FOEHR MATTHEW W	President and COO	Aug 24	Sale	110.89	78	8,649	155,413	Aug 25 07:10 PM
FOEHR MATTHEW W	President and COO	Aug 21	Option Exercise	20.38	8,015	163,338	162,638	Aug 25 07:10 PM
FOEHR MATTHEW W	President and COO	Aug 21	Sale	112.88	7,225	815,541	155,413	Aug 25 07:10 PM
HIGGINS JOHN L	Chief Executive Officer	Jul 07	Option Exercise	70.01	4,315	302,098	204,571	Jul 09 04:28 PM
Berkman Charles S	SVP, Gen. Counsel & Secretary	Jun 04	Sale	118.59	11,146	1,321,775	40,877	Jun 05 04:07 PM
FOEHR MATTHEW W	President and COO	Mar 13	Option Exercise	21.92	2,000	43,840	157,449	Mar 13 06:33 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience